Preclinical evaluation of tolvaptan and salsalate combination therapy in a <i>Pkd1</i>-mouse model.

All of these changes (except p-SRC/SRC levels) were significantly attenuated by all treatments, and the combined treatment tended to reduce the levels of p-S6K1/S6K1 ratio, p-ERK/ERK, PCNA and CDK2 as compared to mice treated with salsalate or tolvaptan alone, although the difference did not reach statistical significance ( Figure 2 ). 3.4 Combined salsalate and tolvaptan treatment attenuated kidney injury, inflammation and fibrosis Kidney injury, inflammation, and fibrosis are common findings in ADPKD ( Weimbs, 2007 ; Song et al., 2017 ; Formica and Peters, 2020 ; Zimmerman et al., 2020 ).

also in 111,027 other papers